Irbesartan lowers blood pressure and ameliorates renal injury in experimental non-insulin-dependent diabetes mellitus

M. P. O'Donnell, G. S. Crary, H. Oda, B. L. Kasiske, J. R. Powell, W. F. Keane

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Abstract

In the present study, we investigated the effects of the angiotensin (Ang) II receptor antagonist, irbesartan, on blood pressure and renal structural injury in obese Zucker rats (OZR), an experimental model of non- insulin-dependent diabetes mellitus (NIDDM). Twenty-six-week-old OZR with established renal disease were administered either low-dose (15 mg/kg) or high-dose (50 mg/kg) irbesartan in the drinking water for a period of 18 weeks. Irbesartan caused dose-related reductions in blood pressure, and reduced by 47 to 60% the percent of glomeruli with sclerosis at 44 weeks of age (P < 0.05). In addition, irbesartan at the higher dose reduced the tubulointerstitial injury score at 44 weeks by approximately 75% (P < 0.05). By contrast, irbesartan did not significantly reduce albuminuria in OZR. The results of the present study demonstrate that the Ang II receptor antagonist irbesartan can reduce blood pressure and ameliorate glomerular and tubulointerstitial injury in an experimental model of NIDDM.

Original languageEnglish (US)
Pages (from-to)S218-S220
JournalKidney International, Supplement
Volume51
Issue number63
StatePublished - Dec 1 1997

Keywords

  • Angiotensin II receptor blockers
  • Irbesartan
  • Renin-angiotensin system

Fingerprint Dive into the research topics of 'Irbesartan lowers blood pressure and ameliorates renal injury in experimental non-insulin-dependent diabetes mellitus'. Together they form a unique fingerprint.

Cite this